Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Newron Pharmaceuticals SpA ( (CH:NWRN) ) has shared an announcement.
Newron Pharmaceuticals announced the presentation of data on Evenamide, its lead drug candidate, at the World Congress of Biological Psychiatry 2025. Evenamide, a glutamate release modulator, is being developed as an add-on therapy for schizophrenia patients who do not respond adequately to second-generation antipsychotics. The company presented results from Study 008A, which demonstrated significant efficacy and tolerability of Evenamide as an add-on treatment. Additionally, the ENIGMA-TRS 1 study aims to further evaluate Evenamide’s efficacy in treatment-resistant schizophrenia, with plans to enroll over 600 subjects globally. These developments could potentially enhance Newron’s position in the CNS disorder treatment market and offer new hope for patients with limited treatment options.
The most recent analyst rating on (CH:NWRN) stock is a Hold with a CHF8.50 price target. To see the full list of analyst forecasts on Newron Pharmaceuticals SpA stock, see the CH:NWRN Stock Forecast page.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system disorders. Based in Bresso, near Milan, Italy, Newron’s lead drug candidate is Evenamide, a first-in-class glutamate modulator aimed at treating treatment-resistant schizophrenia and patients inadequately responding to current therapies. The company has a proven track record with CNS therapies, including the Parkinson’s drug Xadago® (Safinamide), and holds licensing agreements for Evenamide’s development and commercialization in Asia.
Average Trading Volume: 49,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: CHF168.1M
Learn more about NWRN stock on TipRanks’ Stock Analysis page.